Kalkine: EVE Health Group Targets Major Therapeutic Markets with New Oral Treatments in ASX200 Healthcare Push

2 min read | June 02, 2025 02:01 PM AEST | By Team Kalkine Media

Google News:

Kalkine: EVE Health Group Targets Major Therapeutic Markets with New Oral Treatments in ASX200 Healthcare Push — Image source: Shutterstock

Recent News

Iron Ore Giants Adjust as Simandou Reshapes Market

ASX Mining Dividends: Fortescue vs Rio Tinto vs BHP

Lithium Stocks Ignite as ASX Battery Boom Returns

Can ASX 300 Lithium Stocks Sustain Gains as Spodumene Prices Tighten?

Make Kalkine Media
My Trusted Source

Highlights

EVE starts stability testing for ED and period pain treatments

Technical milestone supports regulatory pathway

Nextract acquisition boosts pharmaceutical innovation

EVE Health Group (ASX:EVE) has commenced stability testing for its advanced oral formulation products designed to address two major therapeutic needs—erectile dysfunction (ED) and dysmenorrhoea (period pain). This move marks a significant step toward regulatory approval and commercial launch in Australia and beyond.

Stability testing is a core requirement in pharmaceutical development. It ensures that a drug retains its intended safety, efficacy, and quality over time under various environmental conditions. This includes assessing physical, chemical, and microbiological properties. The data gathered during this phase plays a crucial role in preparing a technical dossier for submission to the Therapeutic Goods Administration (TGA), Australia's regulatory authority for therapeutic goods.

EVE Health has already completed both sponsor and manufacturer registration with the TGA and anticipates formal product approval before the end of the year. The oral treatments under evaluation include a dissolvable, alcohol-free strip for ED and a natural, non-hormonal therapy for dysmenorrhoea. Both are targeted at addressing gaps in treatment, particularly where existing options are either slow to act or not well tolerated by patients.

The potential market for these therapies is substantial. Industry estimates place the global ED market at around US$5.3 billion, while the dysmenorrhoea market is valued at approximately US$10.9 billion. By addressing unmet clinical needs with innovative delivery formats, EVE is positioning itself for meaningful impact in the health and wellness segment.

This development also coincides with EVE’s recent acquisition of Nextract, an Australian biotech company known for reformulating established active pharmaceutical ingredients (APIs) into novel, faster-acting delivery systems. Shareholders recently approved the $3 million acquisition, which EVE believes will enhance its formulation and solubility science capabilities. The collaboration aims to streamline the path from research to market-ready products and complements the company’s broader strategy in regulated healthcare markets.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.